Actively Recruiting
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-05-13
110
Participants Needed
7
Research Sites
111 weeks
Total Duration
On this page
Sponsors
N
Nanjing Leads Biolabs Co.,Ltd
Lead Sponsor
P
Peking University Cancer Hospital & Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
CONDITIONS
Official Title
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Agree to follow the treatment plan, visit schedule, lab tests, and other protocol requirements, and provide informed consent
- Age 18 years or older at enrollment
- ECOG performance status score of 0 or 1
- Expected survival of at least 12 weeks
- At least one measurable tumor lesion based on RECIST 1.1 criteria
- Histologically confirmed unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
- Adequate organ and bone marrow function based on lab tests
- Males with fertility and females of childbearing age willing to use effective contraception from consent to 6 months after last study drug dose; women of childbearing age must have a negative pregnancy test within 7 days before first dose
You will not qualify if you...
- Participation in other anticancer drug studies within 4 weeks before starting study drug or planned use of other systemic anti-tumor therapies during the study
- Use of immunomodulatory drugs within 2 weeks before starting study drug
- Active or recurrent autoimmune diseases
- Clinically uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage or intervention
- History of immunodeficiency, including HIV positive status
- Active hepatitis B or C infection
- Pregnancy or lactation
- Any other conditions deemed by the investigator to affect compliance or suitability for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China, 100070
Not Yet Recruiting
2
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
3
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050000
Not Yet Recruiting
4
Shandong Cancer Hospital
Jinan, Shandong, China, 250117
Not Yet Recruiting
5
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China, 266000
Not Yet Recruiting
6
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China, 030013
Not Yet Recruiting
7
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China, 300202
Not Yet Recruiting
Research Team
L
Lin Shen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here